Compare MGM Resorts International (MGM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs State Street SPDR S&P Biotech ETF — how do they compare? MGM Resorts International trades at $29.27 (market cap $7.55B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MGM | XBI | |
|---|---|---|
Market Cap | $7.55B | $10.11B |
Volume | 5,342,346 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $50.69 | $169.55 |
52-Week Low | $29.27 | $104.99 |
Typical Hold Time | 91 Days | 38 Days |
Enterprise Value | $34.85B | — |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $30.01, showing minimal daily movement. The stock is in a bearish technical trend with recent pressure following the collapse of a proposed acquisition by Barry Diller's People Inc. Fundamentally, revenue remains stable near $17.5 billion, but net income margin has compressed to 2.4% in 2025. The company maintains strong operating cash flow of $2.53 billion, though net cash flow was negative $338 million. Analyst sentiment is mixed but leans positive, with a consensus price target of $48.75 implying significant upside.
The investment outlook for MGM hinges on its ability to stabilize profitability and navigate deal uncertainty. The primary opportunity lies in the substantial discount to analyst targets, while risks include execution on potential acquisitions, competitive pressures in the gaming sector, and macroeconomic sensitivity. The stock's current valuation multiples, such as a P/E of 18.19, appear reasonable if earnings can recover.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
